Literature DB >> 26906474

Synthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.

Daniel E Beck1, Wei Lv1, Monica Abdelmalak2, Caroline B Plescia2, Keli Agama2, Christophe Marchand2, Yves Pommier2, Mark Cushman3.   

Abstract

Fluorine and chlorine are metabolically stable, but generally less active replacements for a nitro group at the 3-position of indenoisoquinoline topoisomerase IB (Top1) poisons. A number of strategies were employed in the present investigation to enhance the Top1 inhibitory potencies and cancer cell growth inhibitory activities of halogenated indenoisoquinolines. In several cases, the new compounds' activities were found to rival or surpass those of similarly substituted 3-nitroindenoisoquinolines, and several unusually potent analogs were discovered through testing in human cancer cell cultures. A hydroxyethylaminopropyl side chain on the lactam nitrogen of two halogenated indenoisoquinoline Top1 inhibitors was found to also impart inhibitory activity against tyrosyl DNA phosphodiesterases 1 and 2 (TDP1 and TDP2), which are enzymes that participate in the repair of DNA damage induced by Top1 poisons.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anticancer; Cytotoxicity; Indenoisoquinoline; Topoisomerase I; Tyrosyl DNA phosphodiesterase 1; Tyrosyl DNA phosphodiesterase 2

Mesh:

Substances:

Year:  2016        PMID: 26906474      PMCID: PMC4789169          DOI: 10.1016/j.bmc.2016.02.015

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  32 in total

1.  Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.

Authors:  M Cushman; M Jayaraman; J A Vroman; A K Fukunaga; B M Fox; G Kohlhagen; D Strumberg; Y Pommier
Journal:  J Med Chem       Date:  2000-10-05       Impact factor: 7.446

2.  Improved protein-ligand docking using GOLD.

Authors:  Marcel L Verdonk; Jason C Cole; Michael J Hartshorn; Christopher W Murray; Richard D Taylor
Journal:  Proteins       Date:  2003-09-01

3.  Cellular topoisomerase I inhibition and antiproliferative activity by MJ-III-65 (NSC 706744), an indenoisoquinoline topoisomerase I poison.

Authors:  Smitha Antony; Glenda Kohlhagen; Keli Agama; Muthusamy Jayaraman; Shousong Cao; Farukh A Durrani; Youcef M Rustum; Mark Cushman; Yves Pommier
Journal:  Mol Pharmacol       Date:  2004-11-05       Impact factor: 4.436

4.  Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.

Authors:  Daniel E Beck; Monica Abdelmalak; Wei Lv; P V Narasimha Reddy; Gabrielle S Tender; Elizaveta O'Neill; Keli Agama; Christophe Marchand; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2015-04-24       Impact factor: 7.446

5.  A model for the mechanism of human topoisomerase I.

Authors:  L Stewart; M R Redinbo; X Qiu; W G Hol; J J Champoux
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

6.  Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.

Authors:  M R Redinbo; L Stewart; P Kuhn; J J Champoux; W G Hol
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

7.  Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.

Authors:  Muthukaman Nagarajan; Andrew Morrell; Brian C Fort; Marintha Rae Meckley; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2004-11-04       Impact factor: 7.446

8.  Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors.

Authors:  Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

Review 9.  Camptothecin: current perspectives.

Authors:  Craig J Thomas; Nicolas J Rahier; Sidney M Hecht
Journal:  Bioorg Med Chem       Date:  2004-04-01       Impact factor: 3.641

10.  Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.

Authors:  Smitha Antony; Muthusamy Jayaraman; Gary Laco; Glenda Kohlhagen; Kurt W Kohn; Mark Cushman; Yves Pommier
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  8 in total

1.  New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).

Authors:  Carlos J A Ribeiro; Jayakanth Kankanala; Ke Shi; Kayo Kurahashi; Evgeny Kiselev; Azhar Ravji; Yves Pommier; Hideki Aihara; Zhengqiang Wang
Journal:  Eur J Pharm Sci       Date:  2018-03-21       Impact factor: 4.384

2.  Triazolopyrimidine and triazolopyridine scaffolds as TDP2 inhibitors.

Authors:  Carlos J A Ribeiro; Jayakanth Kankanala; Jiashu Xie; Jessica Williams; Hideki Aihara; Zhengqiang Wang
Journal:  Bioorg Med Chem Lett       Date:  2018-11-22       Impact factor: 2.823

3.  The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.

Authors:  Laetitia Marzi; Yilun Sun; Shar-Yin N Huang; Amy James; Simone Difilippantonio; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2020-05-19       Impact factor: 6.261

4.  Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.

Authors:  Jayakanth Kankanala; Carlos J A Ribeiro; Evgeny Kiselev; Azhar Ravji; Jessica Williams; Jiashu Xie; Hideki Aihara; Yves Pommier; Zhengqiang Wang
Journal:  J Med Chem       Date:  2019-04-30       Impact factor: 7.446

5.  The influence of an enamine usnic acid derivative (a tyrosyl-DNA phosphodiesterase 1 inhibitor) on the therapeutic effect of topotecan against transplanted tumors in vivo.

Authors:  V P Nikolin; N A Popova; V I Kaledin; O A Luzina; A L Zakharenko; N F Salakhutdinov; O I Lavrik
Journal:  Clin Exp Metastasis       Date:  2021-08-09       Impact factor: 5.150

6.  Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Authors:  Laetitia Marzi; Keli Agama; Junko Murai; Simone Difilippantonio; Amy James; Cody J Peer; William D Figg; Daniel Beck; Mohamed S A Elsayed; Mark Cushman; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2018-05-10       Impact factor: 6.261

7.  Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity.

Authors:  Mostafa M Elbadawi; Wagdy M Eldehna; Wenjie Wang; Keli K Agama; Yves Pommier; Manabu Abe
Journal:  Eur J Med Chem       Date:  2021-02-09       Impact factor: 7.088

Review 8.  Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.

Authors:  Mary-Ann Bjornsti; Scott H Kaufmann
Journal:  F1000Res       Date:  2019-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.